Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 150
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 151
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
LATEST NEWS UPDATES | Price cut on TB drug to expand access

Price cut on TB drug to expand access

Share this article Share this article
published Published on Dec 20, 2022   modified Modified on Dec 21, 2022

-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.

The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.

Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM – a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.

Treatment previously recommended has been limited, expensive, toxic, and lengthy – requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.

In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.

Please click here to read more. 


The Hindu Business Line, 20 December, 2022, https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece


Related Articles

 

Write Comments

Your email address will not be published. Required fields are marked *

*

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close